Literature DB >> 30569223

Endovascular treatment for unruptured aneurysm associated with persistent primitive trigeminal artery: a case report and literature review.

Satoshi Murai1, Kenji Sugiu2, Tomohito Hishikawa1, Masafumi Hiramatsu1, Shingo Nishihiro1, Naoya Kidani1, Yu Takahashi1, Isao Date1.   

Abstract

The persistent primitive trigeminal artery (PPTA) is the most common carotid-basilar anastomosis, and the incidence of cerebral aneurysms associated with the PPTA is approximately 4%. Since PPTA aneurysms often have a wide neck and other vascular anomalies, endovascular treatment using an adjunctive technique is the current first-line therapy. Here, we report a case of PPTA aneurysm treated by coil embolization with a stent-assisted technique. A detailed evaluation of the size and course of all vessels and collateral flow, including the Allcock test and balloon test occlusion, is necessary when deciding on the treatment strategy.

Entities:  

Keywords:  Balloon test occlusion; Cerebral aneurysm; Coil embolization; Persistent primitive trigeminal artery; Stent-assisted technique

Year:  2018        PMID: 30569223     DOI: 10.1007/s00701-018-3767-6

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  3 in total

1.  Endovascular treatment of a ruptured aneurysm arising from the proximal end of a partial vertebrobasilar duplication with a contralateral prominent persistent primitive hypoglossal artery: illustrative case.

Authors:  Nobuyuki Genkai; Kouichirou Okamoto; Toshiharu Nomura; Hiroshi Abe
Journal:  J Neurosurg Case Lessons       Date:  2021-05-10

2.  Unruptured Paraclinoid Carotid Aneurysms Occur More Frequently in Younger Ages.

Authors:  Reo Kawaguchi; Shigeru Miyachi; Tomotaka Ohshima; Naoki Matsuo
Journal:  Neurointervention       Date:  2021-05-24

Review 3.  Clinical Importance of the Persistent Primitive Trigeminal Artery in Vascular Lesions and Its Role in Endovascular Treatment.

Authors:  Yiheng Wang; Jinlu Yu
Journal:  Front Neurol       Date:  2022-07-11       Impact factor: 4.086

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.